You can also read more about our study or download the full report.
Table showing potential reduction in high blood pressure (hypertension)
Prevalent hypertension cases avoided among the UK population (by sex) under the intervention scenario relative to baseline, 2021–35.
| Year |
Male |
Female |
| 2021 |
-21,366.70 |
-21,620.00
|
| 2022 |
150,546.20 |
112,095.60 |
| 2023 |
364,447.70 |
181,673.60 |
| 2024 |
576,253.10 |
259,076.30 |
| 2025 |
618,512.10 |
276,268.10 |
| 2026 |
660,096.60 |
293,101.30 |
| 2027 |
702,422.70 |
309,502.40 |
| 2028 |
747,587.40 |
325,494.80 |
| 2029 |
794,452.20 |
342,254.40 |
| 2030 |
842,933.60 |
358,623.20 |
| 2031 |
878,743.90 |
365,880.30 |
| 2032 |
914,105.30 |
373,528.70 |
| 2033 |
948,224.70 |
379,852.20 |
| 2034 |
983,877.90 |
386,145.90 |
| 2035 |
1,016,927.50 |
390,223.50 |
Table showing potential increase in quality-adjusted life years
Cumulative quality-adjusted life years gained (by sex) under the intervention scenario relative to baseline, 2021–35.
| Year |
Male |
Female |
| 2021 |
-77
|
159
|
| 2022 |
1,487 |
741
|
| 2023 |
4,914 |
2,812
|
| 2024 |
12,246 |
7,684
|
| 2025 |
22,319 |
15,901
|
| 2026 |
35,029 |
26,820
|
| 2027 |
50,196 |
40,102
|
| 2028 |
67,887 |
55,623
|
| 2029 |
87,274 |
73,438
|
| 2030 |
108,992 |
93,383
|
| 2031 |
132,445 |
115,578
|
| 2032 |
158,025 |
139,697
|
| 2033 |
184,826 |
165,328
|
| 2034 |
213,057 |
192,347
|
| 2035 |
242,624 |
220,922
|
Tables showing potential cost savings
Costs avoided (direct, indirect and total) under the intervention scenario relative to baseline, 2021–35.
Direct costs avoided (millions of pounds)
| Year |
Coronary heart disease |
Stroke |
Hypertension |
| 2021 |
0
|
1
|
-14
|
| 2022 |
3 |
15 |
85 |
| 2023 |
9 |
23 |
177 |
| 2024 |
20 |
47 |
271 |
| 2025 |
27 |
61 |
290 |
| 2026 |
35 |
74 |
309 |
| 2027 |
44 |
83 |
329 |
| 2028 |
51 |
95 |
348 |
| 2029 |
58 |
97 |
369 |
| 2030 |
64 |
110 |
390 |
| 2031 |
70 |
116 |
404 |
| 2032 |
76 |
129 |
418 |
| 2033 |
80 |
133 |
431 |
| 2034 |
84 |
142 |
445 |
| 2035 |
87 |
150 |
457 |
Indirect costs avoided (millions of pounds)
| Year |
Coronary heart disease |
Stroke |
| 2021 |
-1.3
|
2.3
|
| 2022 |
8.7
|
32
|
| 2023 |
24.9
|
51
|
| 2024 |
52.9
|
103.1
|
| 2025 |
73.5
|
134.6
|
| 2026 |
94.7
|
161.6
|
| 2027 |
117.6
|
181.8
|
| 2028 |
138.3
|
207.4
|
| 2029 |
155.7
|
212.5
|
| 2030 |
172.3
|
240.4
|
| 2031 |
188.8
|
254.6
|
| 2032 |
204
|
282.2
|
| 2033 |
214.4
|
290.7
|
| 2034 |
225.6
|
310.4
|
| 2035 |
235.4 |
329.8
|
Total costs avoided (millions of pounds)
| Year |
Direct |
Indirect |
| 2021 |
-13
|
1
|
| 2022 |
103 |
40.7 |
| 2023 |
209 |
76 |
| 2024 |
338 |
156.1 |
| 2025 |
378 |
208.1 |
| 2026 |
418 |
256.3 |
| 2027 |
456 |
299.4 |
| 2028 |
494 |
345.7 |
| 2029 |
524 |
368.1 |
| 2030 |
564 |
412.7 |
| 2031 |
590 |
443.4 |
| 2032 |
623 |
486.2 |
| 2033 |
644 |
505.1 |
| 2034 |
671 |
536 |
| 2035 |
694 |
565.2 |
